• PDGF-BB: Identity, Mechanism, and Evidence Scope

  2026-10-15

  APExBIO’s product description defines murine recombinant PDGF-BB as a non-glycosylated, E. coli-expressed PDGF-BB homodimer with reported receptor context and dose-dependent activity in BALB/c 3T3 cells. Those claims support a product-identity and measurement overview, but not an independent assessment of mechanism, cross-model potency, or therapeutic relevance.

• BCIP/NBT AP Kit: Evidence and Scope

  2026-10-15

  The Alkaline Phosphatase Substrate Test Kit, SKU K4151, is documented by APExBIO as a BCIP/NBT chromogenic system for visualizing alkaline phosphatase activity. Its described chemistry supports a qualitative color-development principle, but no identity-matched research paper or independent performance dataset was provided; application-specific sensitivity, selectivity, reproducibility, quantitative validity, and clinical relevance therefore remain unverified.

• When Context Changes What an MMP9 Result Means

  2026-10-14

  The same MMP9-related result can signify different biology depending on the model, perturbation, and readout. In a recent mouse study, Adamtsl3 loss in parvalbumin interneurons was linked to perineuronal-net disruption and renewed adult visual-cortex plasticity. That mechanistic context is distinct from the tumor metastasis, angiogenesis, and cerebral-ischemia contexts used to describe SB-3CT. The distinction matters: a gelatinase inhibitor may be conceptually relevant to the pathway without being evidence that a particular commercial material was used, selective in the relevant tissue, or capable of reproducing the reported phenotype.

• Bufalin and CENPA: What HCC Evidence Shows

  2026-10-14

  A pre-proof study links Bufalin with reduced CENPA expression, glycolytic activity, and migratory behavior in hepatocellular carcinoma models. The findings are mechanistically suggestive but remain preliminary: computational docking, cell-based assays, and pilot xenograft staining do not establish direct binding, clinical efficacy, or safety.

• PI Nanoliposomes and Cellular Immunity

  2026-10-13

  A source-grounded editorial overview of a 2026 Journal of Controlled Release study proposing phosphatidylinositol-based nanoliposomes as self-adjuvanting, endoplasmic-reticulum-targeting vaccine carriers. The reported mouse findings suggest stronger CD8 T-cell responses and tumor control than MF59-adjuvanted ovalbumin, while the supplied evidence remains limited by its condensed, pre-proof format and lack of detailed quantitative results.

• Hoechst 33258 in KRas Tumor Mechanobiology

  2026-10-13

  A source-grounded overview of Hoechst 33258 as a DNA-imaging reagent and of reported links between KRas transfer, tunneling nanotubes, and tumor-cell mechanics. The evidence supports a mechanistic hypothesis in cell-based models, but does not establish clinical utility or prove that membrane mechanics alone drive metastasis.

• 7-dehydro Cholesterol and Antiviral Fish Biology

  2026-10-12

  A 2026 Aquaculture Reports study identified dhcr7 as a candidate genetic determinant of grass carp resistance to GCRV-II. The findings connect cholesterol biosynthesis with antiviral immunity in vivo, while leaving important questions about mechanism, long-term fitness, strain breadth and applicability beyond the studied fish model.

• Cisapride and Deep-Learning Cardiotoxicity Evidence

  2026-10-12

  An evidence-bounded overview of Grafton et al.’s iPSC-cardiomyocyte screen, its reported cardiotoxicity signals, and what the study does—and does not—show about Cisapride (R 51619).

• Drug Response Metrics in Cancer Cell Models

  2026-10-10

  Hannah R. Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework that separates growth inhibition from cell killing and emphasizes their different proportions and timing, improving interpretation of in vitro drug-response studies.

• Lactylation–NSUN2 Axis Drives Pancreatic Cancer PNI

  2026-10-09

  A 2026 Theranostics study identifies NSUN2 K692 lactylation as a mechanistic link between lactate accumulation, RNA m5C modification, and perineural invasion in pancreatic ductal adenocarcinoma. Its multi-level evidence supports a lactate–NSUN2–m5C–CDCP1/STC1 axis, while the findings remain primarily preclinical and require further validation in clinically representative cohorts and therapeutic studies.

• Calcitriol and VDR Signaling: Research Evidence

  2026-10-09

  Calcitriol, or 1,25-dihydroxy vitamin D3, is being studied as a regulator of vitamin D receptor signaling across reproductive, immune, skeletal, and cancer biology. Recent in vitro evidence links this pathway to endometrial stromal-cell decidualization, while broader claims involving cytokines, Hedgehog signaling, and clinical outcomes remain context-dependent and require stronger primary-source support.

• Tacalcitol Sensitizes Colorectal Cancer to 5-FU

  2026-10-08

  Milczarek et al. identified a mechanistic basis for tacalcitol-mediated enhancement of 5-fluorouracil activity in HT-29 colorectal cancer cells: VDR-dependent induction of CDKN1A reduces thymidylate synthase at both the transcript and protein levels. The findings support a biomarker-oriented model involving VDR and CaSR, while remaining preclinical and limited to a defined cellular system.

• Perospirone: Receptor Selectivity Meets Vascular Kv1.5

  2026-10-08

  Perospirone (SM-9018 free base) combines high-affinity serotonergic and dopaminergic receptor activity with newly reported inhibition of vascular Kv currents. This evidence-focused analysis explains what the finding adds to schizophrenia research, cardiovascular pharmacology, and neuropsychiatric disorder models—while defining its translational limits.

• From Biotin-Free Labeling to Fluorescent Readouts

  2026-10-07

  The emerging BmTyr proximity-labeling platform shows how biotin-free chemistry can reduce endogenous biotin background in primary T-cell proteomics. This thought-leadership analysis explains why that advance complements, rather than displaces, Streptavidin-HyperFluor 647 for direct fluorescence-based detection of biotinylated targets.

• LIRP Enables Light-Controlled Gene Therapy

  2026-10-07

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic protein production at the translation stage. In mouse models, LIRP-based gene switches enabled light-responsive control of metabolic and retinal therapies, while also highlighting important translational limitations involving light delivery, vector biology, and clinical validation.

8667 records 1/578 page Next 12345 下5页 Last page